Medinews
1 Marzo 2019

FDA Approves TAS-102 for Gastric/GEJ Cancer

February 25, 2019 – The FDA has approved TAS-102 (trifluridine/tipiracil) for adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. The approval is based on data from the phase III TAGS trial, in which TAS-102 reduced the risk of death by about … (leggi tutto)

TORNA INDIETRO